


Ask a doctor about a prescription for LATUDA 18.5 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Latuda 18.5 mg Film-Coated Tablets
Latuda 37 mg Film-Coated Tablets
Latuda 74 mg Film-Coated Tablets
lurasidone
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Keep this package leaflet, as you may need to read it again.
Contents of the Package Leaflet
Latuda contains the active substance lurasidone and belongs to a group of medications called antipsychotics. It is used to treat the symptoms of schizophrenia in adults (18 years of age and older) and adolescents from 13 to 17 years. Lurasidone works by blocking brain receptors that dopamine and serotonin act on. Dopamine and serotonin are neurotransmitters (substances that allow nerve cells to communicate with each other) involved in the symptoms of schizophrenia. By blocking these receptors, lurasidone helps to normalize brain activity, reducing the symptoms of schizophrenia.
Schizophrenia is a disorder with symptoms such as hearing, seeing, or feeling things that do not exist, having false beliefs, exaggerated suspicion, withdrawal, incoherent speech and behavior, and lack of emotions. People suffering from this disorder may feel depressed, anxious, guilty, or tense. This medication is used to improve their schizophrenia symptoms.
Warnings and Precautions
The full effect of this medication may take several days or even weeks to appear.
Consult your doctor if you have any questions about this medication.
Consult your doctor or pharmacist before taking this medication or during treatment, especially if:
If you meet any of these conditions, consult your doctor, as it is possible that they will want to adjust your dose, monitor you more closely, or interrupt treatment with Latuda.
Children and Adolescents
Do not administer to children under 13 years of age.
Other Medications and Latuda
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication. This is especially important if you are taking:
Tell your doctor if you are taking any of these medications, as it is possible that they will need to change the dose of that medication during treatment with Latuda.
The following medications may increase the concentration of lurasidone in your blood:
The following medications may decrease the concentration of lurasidone in your blood:
Tell your doctor if you are taking any of these medications, as it is possible that they will change your dose of Latuda.
Taking Latuda with Food, Drinks, and Alcohol
Consumption of alcohol should be avoided when taking this medication, as it will have a negative additive effect.
Do not drink grapefruit juice while taking this medication. Grapefruit can affect the action of this medication.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
You should not take this medication during pregnancy unless you have agreed to do so with your doctor.
If your doctor decides that the potential benefit of treatment during pregnancy justifies the potential risk to the unborn child, your doctor will closely monitor your child after birth. The reason is that in newborns of mothers who have used lurasidone in the last trimester (last three months) of pregnancy, the following symptoms may appear:
If your child develops any of these symptoms, you should consult your doctor.
It is not known whether lurasidone passes into breast milk. Inform your doctor if you are breastfeeding or plan to breastfeed.
Driving and Using Machines
During treatment with this medication, drowsiness, dizziness, and vision problems (see section 4, Possible side effects) may occur. Do not drive or operate tools or machinery until you know that this medication does not affect you negatively.
Latuda Contains Sodium
Each tablet contains less than 1 mmol of sodium (23 mg), i.e., it is essentially "sodium-free".
Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist again.
Your dose will be decided by your doctor and may depend on:
Adults (18 years or older)
The recommended initial dose is 37 mg once daily.
Your doctor may increase or decrease the dose within the range of 18.5 mg to 148 mg once daily. The maximum dose should not exceed 148 mg once daily.
Adolescents from 13 to 17 years
The recommended initial dose is 37 mg of lurasidone once daily.
The dose may be increased or decreased by your doctor within the dose range of 37 to 74 mg once daily. The maximum daily dose should not exceed 74 mg.
How to Take Latuda
Swallow the tablet whole with water to mask its bitter taste. You should take the dose regularly every day at the same time, so it is easier to remember. You should take this medication with food or immediately after eating, as this helps the body absorb the medication and allows it to work better.
If you take more Latuda than you should
If you take more of this medication than you should, consult your doctor immediately.
You may experience drowsiness, fatigue, abnormal body movements, problems standing and walking, dizziness due to low blood pressure, and abnormal heartbeats.
If you forget to take Latuda
Do not take a double dose to make up for forgotten doses. If you forget to take a dose, take the next dose the day after the forgotten dose. If you forget two or more doses, consult your doctor.
If you stop taking Latuda
If you stop taking this medication, you will lose its effects. You should not stop taking the medication unless your doctor tells you to, as the symptoms may return.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Seek medical attentionimmediately if you notice any of the following symptoms:
Also, the following adverse effects may appear in adults:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Frequency not known (cannot be estimated from available data):
muscle tremors, drowsiness, respiratory or feeding problems
In elderly people with dementia, a small increase in the number of deaths has been reported in patients taking schizophrenia medications compared to those who did not take them.
In adolescents, the following adverse effects may appear:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and the blister after CAD or EXP. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from light.
Medicines should not be thrown away through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This will help protect the environment.
Each 18.5 mg tablet contains lurasidone hydrochloride equivalent to 18.6 mg of lurasidone.
Each 37 mg tablet contains lurasidone hydrochloride equivalent to 37.2 mg of lurasidone.
Each 74 mg tablet contains lurasidone hydrochloride equivalent to 74.5 mg of lurasidone.
hypromellose, magnesium stearate (E 470b), titanium dioxide (E171), macrogol, yellow iron oxide (E172) (present in the 74 mg tablets), indigotine (E132) (present in the 74 mg tablets), and carnauba wax (E903).
Appearance of the product and package contents
Latuda film-coated tablets are available in package sizes containing 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 90 x 1, or 98 x 1 tablets in single-dose aluminum/aluminum blisters.
Not all package sizes may be marketed.
Marketing authorization holder
Angelini Pharma S.p.A. Viale Amelia 70, 00181
Rome - Italy
Manufacturer
Aziende Chimiche Riunite Angelini Francesco ACRAF SPA
Via Vecchia del Pinocchio, 22 60100
Ancona (AN), Italy
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium/ Belgium/ BelgiumCNX Therapeutics Netherlands B.V. | Lithuania/ LithuaniaCNX Therapeutics Netherlands B.V. |
????????? ????? ???????? ???? | Luxembourg/ Luxembourg CNX Therapeutics Netherlands B.V. |
Czech Republic/ Czech Republic Angelini Pharma Ceská republika s.r.o. | Hungary/ Hungary Angelini Pharma Magyarország Kft |
Denmark/ Denmark CNX Therapeutics Netherlands B.V. [email protected] | Malta CNX Therapeutics Netherlands B.V. [email protected] |
Germany/ Germany CNX Therapeutics Netherlands B.V. [email protected] | Netherlands/ Netherlands CNX Therapeutics Netherlands B.V. |
Estonia/ Estonia CNX Therapeutics Netherlands B.V. [email protected] | Norway/ Norway CNX Therapeutics Netherlands B.V. [email protected] |
Greece/ Greece Angelini Pharma Hellas Μονοπρ?σωπη ABEE | Austria/ Austria Angelini Pharma Österreich GmbH |
Spain/ Spain ANGELINI PHARMA ESPAÑA, S.L. Tel: + 34 93 253 45 00 | Poland/ Poland Angelini Pharma Polska Sp. z o.o. |
France CNX Therapeutics Netherlands B.V. | Portugal Angelini Pharma Portugal, Unipessoal Lda |
Croatia/ Croatia Aziende Chimiche Riunite Angelini Francesco – A.C.R.A.F. S.p.A. Tel: + 39 06 78 0531 | Romania/ Romania Angelini Pharmaceuticals România SRL |
Ireland CNX Therapeutics Netherlands B.V. | Slovenia/ Slovenia Bonifar d.o.o. Tel: + 386 1 235 0490 |
Iceland/ Iceland CNX Therapeutics Netherlands B.V. [email protected] | Slovak Republic/ Slovak Republic Angelini Pharma Slovenská republika s.r.o. |
Italy/ Italy Angelini S.p.A. Tel: + 39 06 78 0531 | Finland/ Finland CNX Therapeutics Netherlands B.V. |
Cyprus/ Cyprus Angelini Pharma Hellas Μονοπρ?σωπη ABEE | Sweden/ Sweden CNX Therapeutics Netherlands B.V. |
Latvia/ Latvia CNX Therapeutics Netherlands B.V. [email protected] | Northern Ireland CNX Therapeutics Netherlands B.V. |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
The average price of LATUDA 18.5 mg FILM-COATED TABLETS in November, 2025 is around 37.84 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for LATUDA 18.5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.